dacarbazine and Pituitary Neoplasms

dacarbazine has been researched along with Pituitary Neoplasms in 91 studies

Research

Studies (91)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	17 (18.68)	29.6817
2010's	70 (76.92)	24.3611
2020's	4 (4.40)	2.80

Authors

Authors	Studies
McCormack, A	1
Barbot, M; Bergo, E; Caccese, M; Ceccato, F; Cerretti, G; Lombardi, G; Occhi, G; Padovan, M; Scaroni, C	1
Burman, P; Dekkers, OM; Losa, M; McCormack, A; Petersenn, S; Popovic, V; Raverot, G; Theodoropoulou, M; Trouillas, J	1
Geer, EB	1
Assié, G; Batisse-Lignier, M; Bonnet, F; Borot, S; Bourcigaux, N; Bresson, D; Caron, P; Castinetti, F; Chabre, O; Chanson, P; Cloix, L; Cortet, C; Delemer, B; Desailloud, R; Gaillard, S; Garcia, C; Haissaguerre, M; Jouanneau, E; Jublanc, C; Lasolle, H; Lebrun-Frenay, C; Raverot, G; Reznik, Y; Sadoul, JL; Taillandier, L; Vasiljevic, A; Villa, C	1
Ahmad, MM; Aldabas, BS; Aljoaib, NN; Almalki, MH; Alotaibi, MJ; Alshahrani, F; Wahedi, TS	1
Höftberger, R; Knosp, E; Marosi, C; Micko, ASG; Vila, G; Wöhrer, A; Wolfsberger, S	1
Bilbao, I; Egaña, N; García, C; Olaizola, I	1
De Vos, FYFL; Snijders, TJ; Spliet, WGM; Stades, AME; van der Vlist, A	1
Lenders, N; McCormack, A	1
Burman, P; Dekkers, OM; McCormack, A; Petersenn, S; Popovic, V; Raverot, G; Trouillas, J	1
Even-Zohar, N; Greenman, Y	1
Chen, C; Hu, Y; Jiang, S; Wang, M; Yin, S; Zhang, S; Zhou, P	1
Barkhoudarian, G; Eisenberg, A; Kelly, DF; Ogunbameru, R; Palejwala, SK; Wei, H	1
Batisse, M; Chazal, J; Durando, X; Kemeny, JL; Maqdasy, S; Montoriol, PF; Raverot, G; Sturm, N; Tauveron, I; Trouillas, J	1
Bao, X; Cai, F; Dai, C; Deng, K; Feng, M; Guo, K; Jiao, Y; Junji, W; Lian, W; Liu, X; Ma, S; Wang, R; Wei, Z; Xing, B; Yang, Y; Yao, Y; Zhang, B	1
Chhabra, L; Sareen, P; Trivedi, N	1
Hirohata, T; Hoya, K; Ide, F; Ishii, Y; Matsuno, A; Miyamoto, S; Mizutani, A; Murakami, M; Nagashima, H; Nishido, H; Okinaga, H; Osamura, RY; Son, JH; Sugaya, M; Tahara, S; Teramoto, A; Yamada, S; Yamada, SM	1
Chen, W; Du, G; Huang, L; Xiao, Z; Zhao, Y	1
Aboukais, R; Assaker, R; Maurage, CA; Zairi, F	1
Jouanneau, E; Raverot, G; Trouillas, J	1
Cusimano, MD; Di Ieva, A; Kovacs, K; Rotondo, F; Syro, LV	1
Hu, Y; Li, J; Li, W; Lu, Z; Ma, C; Tohti, M; Wang, S; Wang, Y	1
Hirohata, T; Ishii, Y; Matsuno, A	1
Jiang, S; Yin, S; Zhong, C; Zhou, P	1
Bertorelle, R; Boscaro, M; Ceccato, F; D'Avella, D; Denaro, L; Emanuelli, E; Gardiman, MP; Lombardi, G; Manara, R; Milanese, L; Occhi, G; Scanarini, M; Scaroni, C; Zagonel, V	1
Laterra, JJ; Salvatori, R; Strowd, RE	1
Andersen, M; Bengtsson, D; Berinder, K; Burman, P; Feldt Rasmussen, U; Hoybye, C; Johannsson, G; Maiter, D; Petersson, M; Ragnarsson, O; Rasmussen, ÅK; Schrøder, HD; van der Lely, AJ	1
Eloy, JA; Liu, JK; Patel, J	1
Chen, W; Fan, B; Li, T; Xiao, Z; Yang, J; Zhao, Y	1
Curtò, L; Trimarchi, F	1
Bogazzi, F; Cannavo, S; Ceccato, F; Curtò, L; De Marinis, L; Iacovazzo, D; Lombardi, G; Losa, M; Mantovani, G; Mazza, E; Minniti, G; Nizzoli, M; Reni, M; Scaroni, C	1
Bin, X; Bingbing, X; Dongchun, W; Kun, Z; Xiaoli, L; Yuling, Y	1
Brown, PD; Cachia, D; Crane, CH; Kamiya-Matsuoka, C; Mahajan, A; McCutcheon, IE; Nam, JY; Penas-Prado, M; Waguespack, SG	1
DeAngelis, LM; Lin, AL; Sum, MW	1
Lasolle, H; Raverot, G	1
Halevy, C; Whitelaw, BC	1
Arnal, AV; Donovan, LE; Odia, Y; Wang, SH	1
Abbritti, RV; Angileri, FF; Baldari, S; Barresi, V; Cannavò, S; Conti, A; Esposito, F; Ferraù, F; Germanò, A; Priola, SM; Tomasello, F	1
Felker, J; Janss, A; Patterson, B; Wrubel, D	1
Bao, X; Dai, C; Deng, K; Feng, M; Lian, W; Liu, X; Ma, S; Ma, W; Sun, B; Wang, R; Wang, Y; Xing, B; Yao, Y; Zhong, D	1
Chibbaro, S; Clavier, JB; Goichot, B; Lhermitte, B; Proust, F; Todeschi, J	1
Hoostal, S; Lou, E; Peterson, RA; SantaCruz, KS; Touma, W; Wiernik, A	1
Buchfelder, M	1
Braund, WJ; Burt, MG; Campbell, KA; Clark, SJ; Clifton-Bligh, RJ; Cook, RJ; Gill, AJ; Grossman, AB; Little, NS; McCormack, AI; McDonald, KL; Robinson, BG	1
Cayli, SR; Guzel, A; Guzel, E; Sav, A; Senturk, S; Tatli, M	1
Czech, T; Knosp, E; Kotter, MR; Marosi, C; Preusser, M; Widhalm, G; Woehrer, A; Wolfsberger, S	1
Cusimano, MD; Kovacs, K; Mason, W; Mohammed, S; Smyth, H	1
Fukuhara, N; Inoshita, N; Ohashi, K; Okuda, C; Oyama, K; Sano, T; Taguchi, M; Takeshita, A; Takeuchi, Y; Yamada, S	1
Andersen, M; Hagen, C; Hansen, S; Schroeder, HD	1
Matsuno, A	1
Byrne, S; Karapetis, C; Vrodos, N	1
Alameda Hernando, C; Lahera Vargas, M; Varela Da Costa, C	1
Erickson, D; Fealey, ME; Horvath, E; Kovacs, K; Lloyd, RV; McLendon, R; Scheithauer, BW	1
Back, W; Bode, H; Brockmann, MA; Hammes, HP; Lammert, A; Seiz, M; Thomé, C	1
Del Porto, L; Dobson, M; Maartens, NF	1
Assaker, R; Bernier, M; Borson-Chazot, F; Brue, T; Caron, P; Chabre, O; Chanson, P; Cornélius, A; Cortet-Rudelli, C; de Fraipont, F; Dufour, H; Figarella-Branger, D; François, P; Gaillard, S; Jouanneau, E; Muller, M; Passagia, JG; Raverot, G; Salenave, S; Sturm, N; Trouillas, J	1
Bush, ZM; Cunningham, T; Jane, JA; Laws, ER; Longtine, JA; Lopes, MB; Schiff, D; Thorner, MO; Vance, ML	1
Horvath, E; Kovacs, K; Lau, Q; Lloyd, R; Scheithauer, B; Syro, LV	1
Cusimano, M; Gonzalez, R; Horvath, E; Kovacs, K; Lau, Q; Lloyd, R; Ortiz, LD; Scheithauer, BW; Syro, LV; Uribe, H	1
Cangi, MG; Gill, AJ; Losa, M; Mazza, E; McCormack, A; Mortini, P; Motta, M; Reni, M; Talarico, A; Terreni, MR	1
Delashaw, JB; Dillard, TH; Fleseriu, M; Gultekin, SH; Neuwelt, EA; Yedinak, CG	1
Altavilla, G; Cannavò, S; Curtò, L; Ferraù, F; Granata, F; Hofland, LJ; Longo, M; Pitini, V; Torre, ML; Trimarchi, F	1
Aghi, MK; Oh, MC	1
Erickson, D; Fealey, M; Horvath, E; Kovacs, K; Kros, JM; Lau, Q; Lloyd, RV; Salehi, F; Scheithauer, BW	1
Altuntaş, Y; Aydın, Y; Karaman, O; Müslüman, AM; Ozderya, A; Ozkayalar, H; Oztürk, FY; Tanık, C; Zuhur, SS	1
Marucci, G	1
Asano, S; Ishida, Y; Katakami, H; Matsuno, A; Mizutani, A; Murakami, M; Okinaga, H; Ozawa, Y; Takano, K; Yamazaki, K	1
Grossman, AB; McCormack, AI; Wass, JA	1
Hueng, DY; Liu, MY; Ma, HI; Sytwu, HK	1
Altuntaş, Y; Çil, E; Karaman, Ö; Müslüman, AM; Özkayalar, H; Öztürk, FY; Tanik, C; Velet, S; Zuhur, SS	1
Fukuhara, N; Nishioka, H; Yamada, S	1
Borson-Chazot, F; Ducray, F; Favrel, V; Honnorat, J; Jouanneau, E; Raverot, G; Trouillas, J; Wierinckx, A	1
Ersen, A; Fadul, CE; Horvath, E; Kovacs, K; Ortiz, LD; Rotondo, F; Scheithauer, BW; Syro, LV; Uribe, H	1
Annamalai, AK; Antoun, NM; Burnet, NG; Burton, H; Cheow, HK; Dean, AF; Gurnell, M; Halsall, DJ; Jefferies, SJ; Kandasamy, N; Kirollos, RW; Kovacs, K; Pickard, JD; Shaw, AS; Simpson, HL	1
Brue, T; Castinetti, F; Dufour, H; Figarella-Branger, D; Jouanneau, E; Morange, I; Raverot, G; Trouillas, J	1
Barlier, A; Barrie, M; Brue, T; Castinetti, F; Conte-Devolx, B; Dufour, H; Morange, I; Philippon, M; Taieb, D	1
Fadul, CE; Horvath, E; Kovacs, K; Ortiz, LD; Rotondo, F; Scheithauer, BW; Syro, LV; Uribe, H	1
Clifton-Bligh, R; Cook, R; Gill, AJ; Kaplan, W; Little, N; McCormack, A; Robinson, B	1
Abrial, C; Durando, X; Gadea, E; Gimbergues, P; Planchat, E; Tatar, Z; Thivat, E	1
Ersen, A; Horvath, E; Kovacs, K; Ortiz, LD; Penagos, L; Rotondo, F; Scheithauer, BW; Syro, LV; Uribe, H	1
Amano, K; Arita, K; Asano, K; Fujio, S; Fukuhara, N; Hirohata, T; Hizuka, N; Ikeda, H; Ishii, Y; Isozaki, O; Iwai, Y; Kawamata, T; Matsuno, A; Nishioka, H; Ogawa, Y; Osamura, RY; Sakata, K; Shimatsu, A; Tahara, S; Takano, K; Takano, S; Teramoto, A; Tominaga, A; Yamada, S	1
Bao, X; Cai, F; Dai, C; Feng, M; Guo, K; Li, G; Lian, W; Liu, X; Ma, S; Ma, W; Wang, J; Wang, R; Xiao, J; Xing, B; Yang, Y; Yao, Y; Zhang, B; Zhang, H	1
Isayama, Y; Kawashima, K; Takashima, H	1
Heaney, AP; Lim, S; Maya, MM; Shahinian, H; Yong, W	1
Argon, D; Basa, S; Seçkinel, SA; Tecimer, T; Varol, A	1
Fadul, CE; Horvath, E; Kovacs, K; Ortiz, LD; Penagos, LC; Syro, LV; Uribe, H	2
Fangusaro, J; Finlay, J; Rook, J; Rosser, T	1
Cole, A; Hedges, TR; Lawrence, D; Lechan, RM; Neff, LM; Shucart, W; Tischler, AS; Weil, M; Zhu, JJ	1
Kovacs, K; Lombardero, M; McLendon, RE; Ortiz, LD; Penagos, LC; Scheithauer, BW; Syro, LV; Uribe, H	1

Reviews

26 review(s) available for dacarbazine and Pituitary Neoplasms

Article	Year
Temozolomide in aggressive pituitary tumours and pituitary carcinomas. Best practice & research. Clinical endocrinology & metabolism, 2022, Volume: 36, Issue:6 Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Pituitary Neoplasms; Systematic Reviews as Topic; Temozolomide	2022
Knowing when to discontinue Temozolomide therapy in responding aggressive pituitary tumors and carcinomas: a systematic review and Padua (Italy) case series. Expert review of endocrinology & metabolism, 2023, Volume: 18, Issue:2 Topics: Adenoma; Antineoplastic Agents, Alkylating; Carcinoma; Dacarbazine; Humans; Pituitary Neoplasms; Temozolomide	2023
Medical therapy for refractory pituitary adenomas. Pituitary, 2023, Volume: 26, Issue:3 Topics: Adenoma; Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Pituitary Neoplasms; Temozolomide	2023
Temozolomide therapy for resistant prolactin-secreting pituitary adenomas and carcinomas: a systematic review. Hormones (Athens, Greece), 2017, Volume: 16, Issue:2 Topics: Antineoplastic Agents, Alkylating; Carcinoma; Dacarbazine; Humans; Pituitary Neoplasms; Prolactinoma; Temozolomide	2017
Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma). Pituitary, 2018, Volume: 21, Issue:2 Topics: Adenoma; Animals; Cell Transformation, Neoplastic; Dacarbazine; Humans; Pituitary Neoplasms; Temozolomide	2018
Management of NFAs: medical treatment. Pituitary, 2018, Volume: 21, Issue:2 Topics: Adenoma; Dacarbazine; Dopamine Agonists; Female; Humans; Male; Pituitary Neoplasms; Temozolomide	2018
Early Recognition and Initiation of Temozolomide Chemotherapy for Refractory, Invasive Pituitary Macroprolactinoma with Long-Term Sustained Remission. World neurosurgery, 2018, Volume: 118 Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prolactinoma; Temozolomide; Time	2018
Molecular status of pituitary carcinoma and atypical adenoma that contributes the effectiveness of temozolomide. Medical molecular morphology, 2014, Volume: 47, Issue:1 Topics: Adenoma; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Dacarbazine; DNA-Binding Proteins; Humans; O(6)-Methylguanine-DNA Methyltransferase; Pituitary Neoplasms; Temozolomide; Treatment Outcome	2014
Management of endocrine disease: clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies. European journal of endocrinology, 2014, Volume: 170, Issue:4 Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adrenocorticotropic Hormone; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Dacarbazine; Follicle Stimulating Hormone; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Luteinizing Hormone; Pituitary Hormones, Anterior; Pituitary Neoplasms; Prognosis; Prolactin; Prolactinoma; Temozolomide; Thyrotropin	2014
Aggressive pituitary adenomas--diagnosis and emerging treatments. Nature reviews. Endocrinology, 2014, Volume: 10, Issue:7 Topics: Adenoma; Biomarkers, Tumor; Dacarbazine; Humans; Ki-67 Antigen; Neoplasm Invasiveness; Neovascularization, Pathologic; Pituitary Neoplasms; Temozolomide; Tumor Suppressor Protein p53	2014
Treatment of pituitary carcinomas and atypical pituitary adenomas: a review. Neurologia medico-chirurgica, 2014, Volume: 54, Issue:12 Topics: Adenoma; Administration, Oral; Antineoplastic Agents, Alkylating; Cell Transformation, Neoplastic; Combined Modality Therapy; Dacarbazine; Disease Progression; Humans; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Pituitary Gland; Pituitary Hormones; Pituitary Neoplasms; Temozolomide	2014
The role of temozolomide in the treatment of aggressive pituitary tumors. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2015, Volume: 22, Issue:6 Topics: Adenoma; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Dacarbazine; Disease Progression; DNA Damage; DNA Modification Methylases; DNA Repair Enzymes; Humans; Mutation; Neoplasm Recurrence, Local; Pituitary Neoplasms; Temozolomide; Tumor Suppressor Proteins	2015
Is there a role for early chemotherapy in the management of pituitary adenomas? Neuro-oncology, 2016, Volume: 18, Issue:10 Topics: Adenoma; Antineoplastic Agents; Dacarbazine; Humans; Pituitary Neoplasms; Temozolomide	2016
How effective is temozolomide for treating pituitary tumours and when should it be used? Pituitary, 2017, Volume: 20, Issue:2 Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; O(6)-Methylguanine-DNA Methyltransferase; Pituitary Neoplasms; Prolactinoma; Temozolomide; Treatment Outcome	2017
Management of aggressive pituitary adenomas: current treatment strategies. Pituitary, 2009, Volume: 12, Issue:3 Topics: Cabergoline; Dacarbazine; Dopamine Agonists; Ergolines; Female; Humans; Male; Pituitary Neoplasms; Somatostatin; Temozolomide	2009
[Recent trends in the pathophysiology and treatment of pituitary adenomas]. Brain and nerve = Shinkei kenkyu no shinpo, 2009, Volume: 61, Issue:8 Topics: Adenoma; Antineoplastic Agents; Cabergoline; Corticotropin-Releasing Hormone; Dacarbazine; Ergolines; Growth Hormone-Releasing Hormone; Human Growth Hormone; Humans; Hypothalamic Hormones; Incidental Findings; Neurosurgical Procedures; Octreotide; Pituitary Neoplasms; Prolactinoma; Receptors, Neuropeptide; Receptors, Pituitary Hormone-Regulating Hormone; Temozolomide	2009
[Treatment of clinically nonfunctioning pituitary adenomas]. Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion, 2010, Volume: 57, Issue:2 Topics: Adenoma; Adult; Cranial Irradiation; Dacarbazine; Decompression, Surgical; Dopamine Agonists; Female; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Hypophysectomy; Male; Neoplasm, Residual; Pituitary Neoplasms; Postoperative Complications; Radiosurgery; Radiotherapy, Intensity-Modulated; Somatostatin; Temozolomide	2010
MGMT immunoexpression in aggressive pituitary adenoma and carcinoma. Pituitary, 2010, Volume: 13, Issue:4 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Humans; Immunohistochemistry; Immunosuppression Therapy; Male; Pituitary Neoplasms; Temozolomide; Tumor Suppressor Proteins	2010
Treatment of pituitary neoplasms with temozolomide: a review. Cancer, 2011, Feb-01, Volume: 117, Issue:3 Topics: Adenoma; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Carcinoma; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Humans; Pituitary Neoplasms; Radiography; Temozolomide; Tumor Suppressor Proteins	2011
Temozolomide-induced shrinkage of a pituitary carcinoma causing Cushing's disease--report of a case and literature review. TheScientificWorldJournal, 2010, Nov-04, Volume: 10 Topics: Adenoma; Adrenocorticotropic Hormone; Adult; Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Male; Pituitary ACTH Hypersecretion; Pituitary Neoplasms; Temozolomide; Treatment Outcome	2010
Dopamine agonist-resistant prolactinomas. Journal of neurosurgery, 2011, Volume: 114, Issue:5 Topics: Antineoplastic Agents, Alkylating; Cell Division; Dacarbazine; Dopamine Agonists; Drug Resistance, Neoplasm; Female; Humans; Male; Mitotic Index; Neoplasm Invasiveness; Pituitary Neoplasms; Prolactin; Prolactinoma; Receptors, Estrogen; Sex Factors; Temozolomide	2011
[Pituitary carcinoma]. Nihon rinsho. Japanese journal of clinical medicine, 2011, Volume: 69 Suppl 2 Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; Middle Aged; Pituitary Neoplasms; Temozolomide	2011
Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature. Pituitary, 2012, Volume: 15, Issue:3 Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Humans; Liver Neoplasms; Male; O(6)-Methylguanine-DNA Methyltransferase; Pituitary Neoplasms; Temozolomide	2012
Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. Clinical endocrinology, 2012, Volume: 76, Issue:6 Topics: Antineoplastic Agents, Alkylating; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Humans; Pituitary Neoplasms; Temozolomide; Tumor Suppressor Proteins	2012
Temozolomide in aggressive pituitary adenomas and carcinomas. Clinics (Sao Paulo, Brazil), 2012, Volume: 67 Suppl 1 Topics: Adenoma; Antineoplastic Agents, Alkylating; Carcinoma; Dacarbazine; Humans; Pituitary Neoplasms; Temozolomide	2012
Temozolomide and unusual indications: review of literature. Cancer treatment reviews, 2013, Volume: 39, Issue:2 Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Lung Neoplasms; Melanoma; Neoplasms; Neuroendocrine Tumors; Pituitary Neoplasms; Temozolomide	2013

Trials

1 trial(s) available for dacarbazine and Pituitary Neoplasms

Article	Year
O(6)-methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas: are progressive tumors potential candidates for temozolomide treatment? Cancer, 2009, Mar-01, Volume: 115, Issue:5 Topics: Adenoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Female; Humans; Immunohistochemistry; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Pituitary Neoplasms; Reoperation; Temozolomide; Time Factors	2009

Article

Year

O(6)-methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas: are progressive tumors potential candidates for temozolomide treatment?

Cancer, 2009, Mar-01, Volume: 115, Issue:5

Topics: Adenoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Female; Humans; Immunohistochemistry; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Pituitary Neoplasms; Reoperation; Temozolomide; Time Factors

2009

Other Studies

64 other study(ies) available for dacarbazine and Pituitary Neoplasms

Article	Year
Initial pathology in aggressive pituitary tumours and carcinomas: 2b or not 2b?-that is the question. European journal of endocrinology, 2023, 04-05, Volume: 188, Issue:4 Topics: Carcinoma; Dacarbazine; Humans; Pituitary Neoplasms; Temozolomide	2023
Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas. European journal of endocrinology, 2017, Volume: 176, Issue:6 Topics: ACTH-Secreting Pituitary Adenoma; Adult; Antineoplastic Agents, Alkylating; Carcinoma; Chemoradiotherapy; Cohort Studies; Dacarbazine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; France; Humans; Male; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Pituitary Neoplasms; Practice Patterns, Physicians'; Prolactinoma; Retrospective Studies; Survival Analysis; Temozolomide; Tumor Burden	2017
MGMT and MSH6 immunoexpression for functioning pituitary macroadenomas. Pituitary, 2017, Volume: 20, Issue:6 Topics: Adult; Antineoplastic Agents, Alkylating; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; DNA-Binding Proteins; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; O(6)-Methylguanine-DNA Methyltransferase; Pituitary Neoplasms; Retrospective Studies; Temozolomide; Tumor Suppressor Proteins	2017
Failure of a second temozolomide cycle in a patient with a prolactin-secreting pituitary carcinoma. Endocrinologia, diabetes y nutricion, 2017, Volume: 64, Issue:10 Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bromocriptine; Cabergoline; Combined Modality Therapy; Dacarbazine; Drug Substitution; Ergolines; Fatal Outcome; Headache; Humans; Hyperprolactinemia; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prolactin; Prolactinoma; Proton Therapy; Temozolomide	2017
Successful treatment of leptomeningeally metastasised pituitary carcinoma with temozolomide. The Netherlands journal of medicine, 2017, Volume: 75, Issue:10 Topics: Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Male; Meningeal Neoplasms; Pituitary Neoplasms; Prolactinoma; Spinal Cord Neoplasms; Temozolomide	2017
Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. European journal of endocrinology, 2018, Volume: 178, Issue:3 Topics: Adenoma; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carcinoma; Carmustine; Child; Child, Preschool; Cranial Irradiation; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Endocrinology; Europe; Female; Humans; Ki-67 Antigen; Male; Middle Aged; Neoplasm Invasiveness; Neurosurgical Procedures; Pituitary Neoplasms; Societies, Medical; Surveys and Questionnaires; Temozolomide; Thalidomide; Tumor Suppressor Proteins; Young Adult	2018
Treatment of aggressive prolactinoma with temozolomide: A case report and review of literature up to date. Medicine, 2017, Volume: 96, Issue:47 Topics: Adolescent; Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Male; Pituitary Neoplasms; Prolactin; Prolactinoma; Salvage Therapy; Temozolomide	2017
Aggressive silent GH pituitary tumor resistant to multiple treatments, including temozolomide. Cancer investigation, 2013, Volume: 31, Issue:3 Topics: Antineoplastic Agents, Alkylating; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Human Growth Hormone; Humans; Ki-67 Antigen; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Temozolomide; Tumor Suppressor Protein p53; Tumor Suppressor Proteins	2013
Pyrimethamine sensitizes pituitary adenomas cells to temozolomide through cathepsin B-dependent and caspase-dependent apoptotic pathways. International journal of cancer, 2013, Oct-15, Volume: 133, Issue:8 Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Caspase 7; Caspase 9; Cathepsin B; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cytochromes c; Dacarbazine; DNA Damage; Drug Synergism; Female; Folic Acid Antagonists; Histones; Leucovorin; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Inbred NOD; Mice, SCID; Mitochondria; Neoplasm Invasiveness; Neoplasm Transplantation; Phosphorylation; Pituitary Neoplasms; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Pyrimethamine; Rats; Temozolomide; Up-Regulation; Xenograft Model Antitumor Assays	2013
Primary undifferentiated spindle-cell sarcoma of sella turcica: successful treatment with adjuvant temozolomide. BMJ case reports, 2013, May-27, Volume: 2013 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Dacarbazine; Diagnosis, Differential; Humans; Male; Pituitary Neoplasms; Sarcoma; Sella Turcica; Temozolomide	2013
HIF-1α inhibition sensitizes pituitary adenoma cells to temozolomide by regulating MGMT expression. Oncology reports, 2013, Volume: 30, Issue:5 Topics: 2-Methoxyestradiol; Adult; Animals; Antineoplastic Agents, Alkylating; Cell Survival; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Estradiol; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Mice; Pituitary Neoplasms; Temozolomide; Tumor Suppressor Proteins	2013
Glioblastoma occurring after the surgical resection of a craniopharyngioma. British journal of neurosurgery, 2014, Volume: 28, Issue:2 Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Clinical Protocols; Craniopharyngioma; Dacarbazine; Glioblastoma; Humans; Immunohistochemistry; Magnetic Resonance Imaging; Male; Neurosurgical Procedures; Pituitary Neoplasms; Temozolomide; Tomography, X-Ray Computed	2014
The expression profile of Dopamine D2 receptor, MGMT and VEGF in different histological subtypes of pituitary adenomas: a study of 197 cases and indications for the medical therapy. Journal of experimental & clinical cancer research : CR, 2014, Jul-16, Volume: 33 Topics: Adenoma; Antibodies, Monoclonal, Humanized; Bevacizumab; Blotting, Western; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Humans; Immunohistochemistry; Male; Pituitary Neoplasms; Receptors, Dopamine D2; Temozolomide; Tumor Suppressor Proteins; Vascular Endothelial Growth Factor A	2014
Pituitary atypical adenoma or carcinoma sensitive to temozolomide combined with radiation therapy: a case report of early identification and management. Turkish neurosurgery, 2014, Volume: 24, Issue:6 Topics: Adenocarcinoma; Adenoma; Adult; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; Pituitary Neoplasms; Temozolomide; Treatment Outcome	2014
Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center. Journal of neuro-oncology, 2015, Volume: 122, Issue:1 Topics: Adenoma; Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Pituitary Neoplasms; Prognosis; Retrospective Studies; Somatostatin; Survival Rate; Temozolomide; Tertiary Care Centers	2015
Temozolomide retreatment in a recurrent prolactin-secreting pituitary adenoma: Hormonal and radiographic response. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2016, Volume: 22, Issue:3 Topics: Adenoma; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prolactin; Prolactinoma; Retreatment; Temozolomide; Treatment Outcome	2016
Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide. The Journal of clinical endocrinology and metabolism, 2015, Volume: 100, Issue:4 Topics: Adenoma; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Pharmacological; Biomarkers, Tumor; Carcinoma; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Follow-Up Studies; Humans; Male; Middle Aged; Pituitary Neoplasms; Prognosis; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins; Young Adult	2015
Disulfiram sensitizes pituitary adenoma cells to temozolomide by regulating O6-methylguanine-DNA methyltransferase expression. Molecular medicine reports, 2015, Volume: 12, Issue:2 Topics: AC133 Antigen; Acetaldehyde Dehydrogenase Inhibitors; Adenoma; Animals; Antigens, CD; Antineoplastic Agents, Alkylating; Bortezomib; Cell Survival; Dacarbazine; Disulfiram; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Nestin; Peptides; Pituitary Neoplasms; Primary Cell Culture; Proteasome Inhibitors; Proteolysis; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Proteins; Ubiquitination; Xenograft Model Antitumor Assays	2015
Authors' Reply to "Pituitary Atypical Adenoma or Carcinoma Sensitive to Temozolomide Combined with Radiation Therapy: A Case Report of Early Identification and Management". Turkish neurosurgery, 2015, Volume: 25, Issue:4 Topics: Adenoma; Dacarbazine; Humans; Male; Pituitary ACTH Hypersecretion; Pituitary Neoplasms	2015
Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas. Journal of neuro-oncology, 2016, Volume: 126, Issue:3 Topics: Adenocarcinoma; Adenoma; Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pituitary Neoplasms; Prognosis; Survival Rate; Temozolomide	2016
HIF-1α Inhibition Sensitized Pituitary Adenoma Cells to Temozolomide by Regulating Presenilin 1 Expression and Autophagy. Technology in cancer research & treatment, 2016, Volume: 15, Issue:6 Topics: Adenoma; Animals; Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Dacarbazine; Hypoxia-Inducible Factor 1, alpha Subunit; Lysosomes; Pituitary Neoplasms; Presenilin-1; Rats; Temozolomide	2016
Radiotherapy with concurrent temozolomide for the management of extraneural metastases in pituitary carcinoma. Pituitary, 2016, Volume: 19, Issue:4 Topics: Adenoma; Adult; Aged; Antineoplastic Agents, Alkylating; Bone Neoplasms; Chemoradiotherapy; Dacarbazine; Female; Humans; Liver Neoplasms; Lymph Nodes; Male; Middle Aged; Neuroendocrine Tumors; Pituitary Neoplasms; Positron-Emission Tomography; Temozolomide	2016
Therapeutic innovations in endocrine diseases - part 3 : temozolomide and future therapeutics for aggressive pituitary tumors and carcinomas. Presse medicale (Paris, France : 1983), 2016, Volume: 45, Issue:6 Pt 2 Topics: Antineoplastic Agents, Alkylating; Carcinoma; Dacarbazine; Forecasting; Humans; Pituitary Neoplasms; Temozolomide	2016
Widely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy. CNS oncology, 2016, Volume: 5, Issue:4 Topics: Adenoma; Adrenocorticotropic Hormone; AMP-Activated Protein Kinase Kinases; Antineoplastic Agents; Brain; Brain Neoplasms; Capecitabine; Dacarbazine; Everolimus; Female; Humans; Ki-67 Antigen; Magnetic Resonance Imaging; Middle Aged; Mutation; Pituitary Neoplasms; Protein Serine-Threonine Kinases; Temozolomide	2016
Aggressive Pituitary Adenomas: The Dark Side of the Moon. World neurosurgery, 2017, Volume: 97 Topics: Adenoma; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Follow-Up Studies; Humans; Image Processing, Computer-Assisted; Ki-67 Antigen; Magnetic Resonance Imaging; Male; Neurosurgical Procedures; Pituitary Neoplasms; Postoperative Complications; Radiotherapy; Retrospective Studies; Temozolomide; Treatment Outcome; Tumor Suppressor Protein p53	2017
Successful treatment of a child with a prolactin secreting macroadenoma with temozolomide. Journal of pediatric endocrinology & metabolism : JPEM, 2016, Dec-01, Volume: 29, Issue:12 Topics: Antineoplastic Agents, Alkylating; Child; Dacarbazine; Female; Humans; Pituitary Neoplasms; Prognosis; Prolactin; Prolactinoma; Temozolomide	2016
Refractory pituitary adenoma: a novel classification for pituitary tumors. Oncotarget, 2016, Dec-13, Volume: 7, Issue:50 Topics: Adenoma; Adult; Aged; Antineoplastic Agents, Alkylating; Biopsy; Cell Proliferation; Dacarbazine; Disease Progression; Drug Resistance, Neoplasm; Fatal Outcome; Female; Humans; Ki-67 Antigen; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Pituitary Neoplasms; Salvage Therapy; Temozolomide; Terminology as Topic; Time Factors; Treatment Outcome; Tumor Burden	2016
An unusual pituitary stalk lesion: What is the place of surgery? Neuro-Chirurgie, 2016, Volume: 62, Issue:6 Topics: Adult; Antineoplastic Agents; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Diabetes Insipidus; Endoscopy; Fatal Outcome; Female; Hemianopsia; Humans; Hypopituitarism; Indoles; Melanoma; Pituitary Neoplasms; Sulfonamides; Temozolomide; Tomography, X-Ray Computed; Vemurafenib	2016
Successful treatment of pituitary carcinoma with concurrent radiation, temozolomide, and bevacizumab after resection. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2017, Volume: 41 Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma; Chemoradiotherapy; Dacarbazine; Humans; Male; Middle Aged; Pituitary Neoplasms; Temozolomide	2017
Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clinical endocrinology, 2009, Volume: 71, Issue:2 Topics: Adult; Cohort Studies; Dacarbazine; Gene Expression; Humans; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Pituitary Neoplasms; Temozolomide	2009
Pituitary carcinoma presenting with multiple metastases: case report. Journal of child neurology, 2008, Volume: 23, Issue:12 Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Dacarbazine; Female; Humans; Magnetic Resonance Imaging; Papilledema; Pituitary Neoplasms; Temozolomide; Tomography, X-Ray Computed	2008
Use of temozolomide in aggressive pituitary tumors: case report. Neurosurgery, 2009, Volume: 64, Issue:4 Topics: Adenoma; Adult; Antineoplastic Agents, Alkylating; Cushing Syndrome; Dacarbazine; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Temozolomide	2009
High incidence of low O(6)-methylguanine DNA methyltransferase expression in invasive macroadenomas of Cushing's disease. European journal of endocrinology, 2009, Volume: 161, Issue:4 Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; Hydrocortisone; Immunohistochemistry; Liver Neoplasms; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Pituitary ACTH Hypersecretion; Pituitary Neoplasms; Temozolomide; Tomography, X-Ray Computed; Young Adult	2009
Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. European journal of endocrinology, 2009, Volume: 161, Issue:4 Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Drug Resistance, Neoplasm; Female; Hormones; Humans; Immunohistochemistry; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Paraffin Embedding; Pituitary Neoplasms; Positron-Emission Tomography; Prolactin; Prolactinoma; Temozolomide; Young Adult	2009
A novel use of temozolomide in a patient with malignant prolactinoma. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2009, Volume: 16, Issue:12 Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Temozolomide	2009
MGMT immunoexpression in silent subtype 3 pituitary adenomas: possible therapeutic implications. Endocrine pathology, 2010, Volume: 21, Issue:3 Topics: Adenoma; Adolescent; Adult; Antineoplastic Agents; Biomarkers, Tumor; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Male; Middle Aged; Pituitary Neoplasms; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins; Young Adult	2010
SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2010, Volume: 118, Issue:10 Topics: Adrenocorticotropic Hormone; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Dacarbazine; Female; Humans; Middle Aged; Pituitary Neoplasms; Salvage Therapy; Somatostatin; Temozolomide; Treatment Outcome	2010
Comment on "Non-surgical treatment of hormone-secreting pituitary tumors". Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2010, Volume: 17, Issue:9 Topics: Adenoma; Clinical Trials as Topic; Dacarbazine; Humans; Pituitary ACTH Hypersecretion; Pituitary Neoplasms; Somatostatin; Temozolomide; Treatment Outcome	2010
Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. The Journal of clinical endocrinology and metabolism, 2010, Volume: 95, Issue:10 Topics: ACTH-Secreting Pituitary Adenoma; Adult; Antineoplastic Agents, Alkylating; Carcinoma; Dacarbazine; DNA Methylation; Female; France; Humans; Male; Middle Aged; Neoplasm Invasiveness; O(6)-Methylguanine-DNA Methyltransferase; Pituitary Neoplasms; Prolactinoma; Retrospective Studies; Sequence Analysis, DNA; Temozolomide	2010
Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression. The Journal of clinical endocrinology and metabolism, 2010, Volume: 95, Issue:11 Topics: Antineoplastic Agents; Dacarbazine; DNA Methylation; Humans; Immunohistochemistry; O(6)-Methylguanine-DNA Methyltransferase; Pituitary Neoplasms; Polymerase Chain Reaction; Promoter Regions, Genetic; Temozolomide; Treatment Outcome	2010
Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases. European journal of endocrinology, 2010, Volume: 163, Issue:6 Topics: Adenoma; Antineoplastic Agents, Alkylating; Carcinoma; Dacarbazine; Female; Humans; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Pituitary Neoplasms; Prospective Studies; Salvage Therapy; Temozolomide	2010
Temozolomide for corticotroph pituitary adenomas refractory to standard therapy. Pituitary, 2011, Volume: 14, Issue:1 Topics: ACTH-Secreting Pituitary Adenoma; Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Male; Middle Aged; Ophthalmoplegia; Pituitary Neoplasms; Temozolomide	2011
MGMT promoter methylation and immunoexpression in aggressive pituitary adenomas and carcinomas. Journal of neuro-oncology, 2011, Volume: 104, Issue:3 Topics: Adenoma; Adolescent; Adult; Antineoplastic Agents, Alkylating; Carcinoma; Dacarbazine; DNA Methylation; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Pituitary Neoplasms; Promoter Regions, Genetic; Statistics as Topic; Temozolomide; Young Adult	2011
MGMT immunoexpression in adamantinomatous craniopharyngiomas. Pituitary, 2011, Volume: 14, Issue:4 Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Biomarkers, Pharmacological; Biomarkers, Tumor; Child; Child, Preschool; Craniopharyngioma; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Humans; Immunohistochemistry; Male; Middle Aged; Pituitary Neoplasms; Prognosis; Temozolomide; Tumor Suppressor Proteins; Young Adult	2011
Treatment of pituitary neoplasms with temozolomide: A review. Cancer, 2011, Sep-01, Volume: 117, Issue:17 Topics: Adenoma; Antineoplastic Agents, Alkylating; Carcinoma; Dacarbazine; Humans; Pituitary Neoplasms	2011
A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report. Neurosurgery, 2011, Volume: 68, Issue:6 Topics: Antineoplastic Agents, Alkylating; Carcinoma; Cell Transformation, Neoplastic; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; DNA-Binding Proteins; Drug Resistance, Neoplasm; Fatal Outcome; Female; Humans; Immunohistochemistry; Middle Aged; Mutation; Pituitary Neoplasms; Prolactin; Prolactinoma; Temozolomide; Tumor Suppressor Protein p53; Tumor Suppressor Proteins	2011
Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status. European journal of clinical investigation, 2011, Volume: 41, Issue:10 Topics: Adenoma; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Carcinosarcoma; Dacarbazine; Humans; O(6)-Methylguanine-DNA Methyltransferase; Pituitary Neoplasms; Temozolomide	2011
Temozolomide and pituitary adenoma. Journal of neurosurgery, 2011, Volume: 114, Issue:6 Topics: Adenoma; Antineoplastic Agents, Alkylating; Dacarbazine; Enzyme-Linked Immunosorbent Assay; Humans; Pituitary Neoplasms; Prolactin; Temozolomide	2011
MGMT immunoexpression in growth hormone-secreting pituitary adenomas and its correlation with Ki-67 labeling index and cytokeratin distribution pattern. Endocrine, 2011, Volume: 40, Issue:2 Topics: Adenoma; Adult; Aged; Antineoplastic Agents, Alkylating; Cell Nucleus; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Female; Human Growth Hormone; Humans; Immunohistochemistry; Keratins; Ki-67 Antigen; Male; Middle Aged; Neoplasm Proteins; Pituitary Neoplasms; Protein Transport; Temozolomide; Tumor Suppressor Proteins	2011
New targeted therapies in pituitary carcinoma resistant to temozolomide. Pituitary, 2012, Volume: 15, Issue:1 Topics: Dacarbazine; Drug Resistance, Neoplasm; Everolimus; Humans; Male; Middle Aged; Pituitary Neoplasms; Sirolimus; Temozolomide	2012
Anti-VEGF therapy in pituitary carcinoma. Pituitary, 2012, Volume: 15, Issue:3 Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Dacarbazine; Humans; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Positron-Emission Tomography; Temozolomide; Vascular Endothelial Growth Factor A	2012
Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment. Annales d'endocrinologie, 2012, Volume: 73, Issue:3 Topics: Adult; Antineoplastic Agents; Carcinoma; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Dopamine Agonists; Hormone Replacement Therapy; Humans; Hyperprolactinemia; Hypophysectomy; Hypopituitarism; Male; Multiple Endocrine Neoplasia Type 1; Mutation, Missense; Neoplasm Recurrence, Local; Ophthalmoplegia; Pancreatic Neoplasms; Parathyroid Neoplasms; Pituitary Apoplexy; Pituitary Neoplasms; Prolactin; Proto-Oncogene Proteins; Radiotherapy, Adjuvant; Remission Induction; Spinal Neoplasms; Temozolomide	2012
MGMT expression and pituitary tumours: relationship to tumour biology. Pituitary, 2013, Volume: 16, Issue:2 Topics: Adult; Aged; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Humans; Male; Middle Aged; Pituitary Neoplasms; Temozolomide; Tumor Suppressor Proteins; Young Adult	2013
Non-uniform response to temozolomide therapy in a pituitary gonadotroph adenoma. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 2012, Volume: 39, Issue:5 Topics: Adenoma; Antineoplastic Agents, Alkylating; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Gonadotrophs; Humans; Ki-67 Antigen; Luteinizing Hormone; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Gland; Pituitary Neoplasms; Temozolomide; Tumor Suppressor Proteins	2012
DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors. The Journal of clinical endocrinology and metabolism, 2013, Volume: 98, Issue:3 Topics: Adenoma; Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Data Collection; DNA Modification Methylases; DNA Repair Enzymes; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Japan; Ki-67 Antigen; Male; Middle Aged; Pituitary Neoplasms; Retrospective Studies; Temozolomide; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Young Adult	2013
Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice. Endocrinology, 2013, Volume: 154, Issue:3 Topics: Adenoma; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Drug Therapy, Combination; Female; Human Growth Hormone; Humans; Mice; Mice, Nude; Phosphoinositide-3 Kinase Inhibitors; Pituitary Neoplasms; Prolactin; Proto-Oncogene Proteins c-akt; Quinoxalines; Signal Transduction; Sulfonamides; Temozolomide; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays	2013
[Hodgkin lymphoma of the nasopharynx associated with a pituitary adenoma]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2003, Volume: 44, Issue:12 Topics: Adenoma; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Dacarbazine; Doxorubicin; Hodgkin Disease; Humans; Hypophysectomy; Male; Middle Aged; Nasopharyngeal Neoplasms; Pituitary Neoplasms; Radiotherapy, Adjuvant; Sphenoid Sinus; Treatment Outcome; Vinblastine	2003
Temozolomide: a novel treatment for pituitary carcinoma. The Lancet. Oncology, 2006, Volume: 7, Issue:6 Topics: Aged; Antineoplastic Agents, Alkylating; Carcinoma; Combined Modality Therapy; Dacarbazine; Humans; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Temozolomide; Treatment Outcome	2006
Craniofacial fibrous dysplasia and hypophysial microadenoma with Hodgkin's lymphoma: unusual involution of an extensive case. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2006, Volume: 64, Issue:8 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Disease Progression; Doxorubicin; Female; Fibrous Dysplasia of Bone; Hodgkin Disease; Humans; Mandibular Diseases; Pituitary Neoplasms; Prolactinoma; Vinblastine	2006
Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm. Clinical endocrinology, 2006, Volume: 65, Issue:4 Topics: Antineoplastic Agents; Dacarbazine; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Temozolomide	2006
Acute transient encephalopathy following paclitaxel treatment in an adolescent with a recurrent suprasellar germinoma. Pediatric blood & cancer, 2008, Volume: 50, Issue:3 Topics: Adolescent; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Carboplatin; Cerebral Ventricle Neoplasms; Combined Modality Therapy; Consciousness Disorders; Cranial Irradiation; Cyclophosphamide; Cytarabine; Dacarbazine; Deoxycytidine; Etoposide; Female; Gemcitabine; Germinoma; Hematopoietic Stem Cell Transplantation; Humans; Hypophysectomy; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pituitary Neoplasms; Temozolomide; Thiotepa; Topotecan	2008
Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: Morphological findings. Human pathology, 2007, Volume: 38, Issue:1 Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Male; Microscopy, Electron; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Temozolomide; Treatment Outcome	2007
Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists. Pituitary, 2007, Volume: 10, Issue:1 Topics: Dacarbazine; Dopamine Agonists; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Temozolomide	2007
MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy. Acta neuropathologica, 2008, Volume: 115, Issue:2 Topics: Antineoplastic Agents, Alkylating; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Humans; Immunohistochemistry; Male; Middle Aged; Pituitary Neoplasms; Temozolomide; Tumor Suppressor Proteins	2008